WO2004014394A1 - 止痒剤 - Google Patents
止痒剤 Download PDFInfo
- Publication number
- WO2004014394A1 WO2004014394A1 PCT/JP2003/010051 JP0310051W WO2004014394A1 WO 2004014394 A1 WO2004014394 A1 WO 2004014394A1 JP 0310051 W JP0310051 W JP 0310051W WO 2004014394 A1 WO2004014394 A1 WO 2004014394A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- integer
- formula
- alkyl
- pharmaceutically acceptable
- Prior art date
Links
- 239000003908 antipruritic agent Substances 0.000 title description 13
- 239000003814 drug Substances 0.000 claims abstract description 37
- 229940079593 drug Drugs 0.000 claims abstract description 32
- 208000003251 Pruritus Diseases 0.000 claims abstract description 30
- 150000003180 prostaglandins Chemical class 0.000 claims abstract description 30
- 150000003839 salts Chemical class 0.000 claims abstract description 30
- 208000024891 symptom Diseases 0.000 claims abstract description 30
- 239000004480 active ingredient Substances 0.000 claims abstract description 23
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 21
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract description 20
- 125000005843 halogen group Chemical group 0.000 claims abstract description 17
- 125000000217 alkyl group Chemical group 0.000 claims description 45
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 33
- -1 C ^ Chemical group 0.000 claims description 30
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 claims description 27
- 230000001823 pruritic effect Effects 0.000 claims description 26
- 125000003342 alkenyl group Chemical group 0.000 claims description 23
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 21
- 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 claims description 20
- 206010003645 Atopy Diseases 0.000 claims description 19
- 125000000304 alkynyl group Chemical group 0.000 claims description 17
- 125000004432 carbon atom Chemical group C* 0.000 claims description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 12
- 125000003545 alkoxy group Chemical group 0.000 claims description 11
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 10
- 201000008937 atopic dermatitis Diseases 0.000 claims description 10
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 10
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 9
- 125000004104 aryloxy group Chemical group 0.000 claims description 9
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 208000002205 allergic conjunctivitis Diseases 0.000 claims description 5
- 208000024998 atopic conjunctivitis Diseases 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000000069 prophylactic effect Effects 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 1
- 208000012657 Atopic disease Diseases 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 229940043274 prophylactic drug Drugs 0.000 claims 1
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 1
- 229940126585 therapeutic drug Drugs 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 7
- 230000007803 itching Effects 0.000 abstract description 5
- 230000002265 prevention Effects 0.000 abstract description 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 47
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 40
- 201000004624 Dermatitis Diseases 0.000 description 18
- 238000012360 testing method Methods 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 13
- 235000019441 ethanol Nutrition 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 210000003491 skin Anatomy 0.000 description 8
- 230000002269 spontaneous effect Effects 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 102000004882 Lipase Human genes 0.000 description 5
- 108090001060 Lipase Proteins 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 5
- 229960001967 tacrolimus Drugs 0.000 description 5
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 239000004367 Lipase Substances 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- 230000001139 anti-pruritic effect Effects 0.000 description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 4
- 238000001647 drug administration Methods 0.000 description 4
- 235000019421 lipase Nutrition 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 239000012046 mixed solvent Substances 0.000 description 4
- 230000033764 rhythmic process Effects 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010040880 Skin irritation Diseases 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 3
- 238000007427 paired t-test Methods 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 230000036556 skin irritation Effects 0.000 description 3
- 231100000475 skin irritation Toxicity 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- 206010063409 Acarodermatitis Diseases 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 208000036741 Pruritus generalised Diseases 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- 241000447727 Scabies Species 0.000 description 2
- 206010048218 Xeroderma Diseases 0.000 description 2
- 206010048222 Xerosis Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 239000000043 antiallergic agent Substances 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 229940125715 antihistaminic agent Drugs 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000031709 bromination Effects 0.000 description 2
- 238000005893 bromination reaction Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000003682 fluorination reaction Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 206010021198 ichthyosis Diseases 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 208000005687 scabies Diseases 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 2
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- ZQXCQTAELHSNAT-UHFFFAOYSA-N 1-chloro-3-nitro-5-(trifluoromethyl)benzene Chemical compound [O-][N+](=O)C1=CC(Cl)=CC(C(F)(F)F)=C1 ZQXCQTAELHSNAT-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000721662 Juniperus Species 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 241000147123 Moorella group Species 0.000 description 1
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 1
- OPKOKAMJFNKNAS-UHFFFAOYSA-N N-methylethanolamine Chemical compound CNCCO OPKOKAMJFNKNAS-UHFFFAOYSA-N 0.000 description 1
- WXAYTPABEADAAB-UHFFFAOYSA-N Oxyphencyclimine hydrochloride Chemical compound Cl.CN1CCCN=C1COC(=O)C(O)(C=1C=CC=CC=1)C1CCCCC1 WXAYTPABEADAAB-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 206010037083 Prurigo Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241001655798 Taku Species 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 210000001557 animal structure Anatomy 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960000456 carbinoxamine maleate Drugs 0.000 description 1
- GVNWHCVWDRNXAZ-BTJKTKAUSA-N carbinoxamine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(OCCN(C)C)C1=CC=C(Cl)C=C1 GVNWHCVWDRNXAZ-BTJKTKAUSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 125000001352 cyclobutyloxy group Chemical group C1(CCC1)O* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000006622 cycloheptylmethyl group Chemical group 0.000 description 1
- 125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- NISGSNTVMOOSJQ-UHFFFAOYSA-N cyclopentanamine Chemical compound NC1CCCC1 NISGSNTVMOOSJQ-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
- 125000001887 cyclopentyloxy group Chemical group C1(CCCC1)O* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000131 cyclopropyloxy group Chemical group C1(CC1)O* 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000006612 decyloxy group Chemical group 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- WCRDXYSYPCEIAK-UHFFFAOYSA-N dibutylstannane Chemical compound CCCC[SnH2]CCCC WCRDXYSYPCEIAK-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Substances CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- ZKCZXVODRKOWIY-UHFFFAOYSA-N diphenylstannane Chemical compound C=1C=CC=CC=1[SnH2]C1=CC=CC=C1 ZKCZXVODRKOWIY-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000003328 mesylation reaction Methods 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005447 octyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005922 tert-pentoxy group Chemical group 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- NHGXDBSUJJNIRV-UHFFFAOYSA-M tetrabutylammonium chloride Chemical compound [Cl-].CCCC[N+](CCCC)(CCCC)CCCC NHGXDBSUJJNIRV-UHFFFAOYSA-M 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000007070 tosylation reaction Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- NFHRNKANAAGQOH-UHFFFAOYSA-N triphenylstannane Chemical compound C1=CC=CC=C1[SnH](C=1C=CC=CC=1)C1=CC=CC=C1 NFHRNKANAAGQOH-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Definitions
- the invention is also directed to pharmaceutical for the prophylaxis or treatment of ⁇ symptoms: cough (hereinafter, positive ⁇ also referred), relates to antipruritic agent which is effective in eliminating ⁇ feeling due especially atopic symptoms.
- drugs such as topical steroids, antihistamines and antiallergic agents have been used for chronic dermatitis.
- the use of steroids is restricted due to the side effects of long-term use, and antihistamines and antiallergic agents have not been sufficiently satisfactory in terms of therapeutic effect.
- pruritic behavior such as histamine and serotonin was previously administered to the skin of animals. Has not been reported to be merely a response to histamine or the like released from mast cells (J. Dermatological Science 25, 20-28, 2001).
- An object of the present invention is to provide a drug for preventing or treating pruritic symptoms based on a new mechanism of action, particularly for preventing or treating atopic symptoms.
- X 1 and X 2 each independently represent a hydrogen atom, a halogen atom or a hydroxyl group
- Y represents an ethylene group, a vinylene group or an ethynylene group
- Z represents a formula
- a and A are the same or different and represent an ethylene group, a vinylene group or an ethynylene group;
- B and B ′ are the same or different and each represent an oxygen atom or a group represented by the formula S ( ⁇ ) u (where u represents an integer of 0 to 2),
- W 1 is a hydroxyl group, C 1 .
- W 2 is an alkyl group of (: ⁇ !, An alkenyl group of C 2 —i, an alkynyl group of c 2 , and c 3
- W 4 represents an alkyl group of, an alkenyl group of, an alkynyl group of, or a 5- alkyl group substituted with a cycloalkyl group of C 3
- V represents an integer of 0 to 4.
- W 3 represents a hydrogen atom or a methyl group, or W 3 is taken together with W 2 and an adjacent carbon atom.
- m represents 0 or 1.
- X 1 and X 2 each independently represent a hydrogen atom, a halogen atom or a hydroxyl group
- Y represents an ethylene group, a vinylene group or an ethynylene group
- Z represents a formula
- k represents an integer of 1 to 4
- h represents an integer of 0 to 4
- q represents an integer of 1 to 4
- r represents an integer of 0 to 4
- t represents an integer of 0 to 2.
- a and A ' are the same or different and each represents an ethylene group, a vinylene group or an ethynylene group;
- B and B ′ are the same or different and each represent an oxygen atom or a group represented by the formula S ( ⁇ ) u (where u represents an integer of 0 to 2),
- W 1 is a hydroxyl group, C or. An alkyloxy group of C 3 .
- W 2 is (: I, alkyl groups, (:.. DOO, alkenyl group, ( ⁇ alkynyl group, C 3 - is substituted with a cycloalkyl group i 0, C 3 _, fl cycloalkyl group.
- C! _ 5 of the alkyl group or the formula was
- W 4 is (:!... Bok alkyl group, Cjj alkenyl group, substituted with a Arukini group or C 3 _ 1D cycloalkyl group
- ⁇ _ 5 represents an alkyl group
- a prostaglandin derivative represented by the formula [1] (provided that 7-[(1R, 2R, 3R, 5R) -5-chloro-2--2-[(1E , 3S) _3-Cyclohexyl-3-Hydroxy-1--1-probenyl] -3-hydroxycyclopentyl]-(5Z) -5-heptenoic acid except).
- a salt or a hydrate thereof comprising a salt or a hydrate thereof as an active ingredient.
- a prostaglandin derivative represented by the formula [1], wherein X 1 is a halogen atom, X 2 is a hydroxyl group, and Y is an ethynylene group, or a pharmaceutically acceptable derivative thereof.
- the present invention provides a drug for preventing or treating pruritic symptoms or for preventing or treating atopic symptoms, comprising a salt or a hydrate thereof as an active ingredient.
- a drug for preventing or treating pruritic symptoms or for preventing or treating atopic symptoms comprising a salt or a hydrate thereof as an active ingredient.
- W 2 is represented by the formula [1]: The alkyl group of,. An alkenyl group, C 2 i. An alkynyl group of. A cycloalkyl group of
- W 4 represents an alkyl group represented by i., An alkenyl group represented by C 2 —i., An alkynyl group represented by, or a 5- alkyl group substituted by a cycloalkyl group represented by C 3 .
- W 3 is a hydrogen atom or a methyl group, a prostaglandin derivative thereof, a pharmaceutically acceptable salt thereof or a hydrate thereof as an active ingredient.
- a drug for preventing or treating the atopic symptoms wherein the atopic symptoms are atopic dermatitis or atopic conjunctivitis.
- an agent for preventing or treating the above-mentioned pruritic symptoms or preventing or treating atopic symptoms which is an external preparation.
- FIG. 1 shows the results of skin irritations (dermatitis scores) observed 4 weeks after drug administration. In the figure, Non represents no treatment, EtOH represents ethanol, and FK506 represents taku and oral limus. * Indicates p ⁇ 0.05.
- FIG. 2 shows the results of a test for suppressing spontaneous pruritus by administering Compound No. 3.
- FIG. 3 shows the results of a test for suppressing spontaneous pruritic behavior by administration of Compound No. 11.
- FIG. 4 shows the results of a test for suppressing spontaneous pruritic behavior by administration of Compound No. 12.
- the present inventors have measured the pruritic behavior of NC / Nga mice that spontaneously develop atopic dermatitis-like skin diseases, and have obtained various measures against spontaneously induced pruritic behavior.
- the antistatic effect of the drug was evaluated.
- a comparative study of the number of pruritus in each animal 24 hours before and after application of the drug showed that the prostaglandins represented by the formula [1] had an excellent effect.
- the antipruritic agent of the present invention will be described.
- the present invention is characterized in that a prostaglandin derivative represented by the formula [1], a pharmaceutically acceptable salt thereof or a hydrate thereof is used as an active ingredient.
- the halogen atom means a fluorine atom, a chlorine atom, a bromine atom or an iodine atom.
- the vinylene group means a cis or trans vinylene group.
- the alkyloxy group means a linear or branched alkyloxy group having 1 to 10 carbon atoms, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butoxy, Examples thereof include a tert-butoxy group, a pentoxy group, a tert-pentyloxy group, a 5-methylhexyloxy group, an octyloxy group, and a decyloxy group.
- Examples of the C 3 — 1 () cycloalkyloxy group include a cyclopropyloxy group, a cyclobutyloxy group, a cyclopentyloxy group, a cyclohexyloxy group, a cyclohexyloxy group, and a cyclononyloxy group. Can be mentioned.
- aryloxy groups include phenoxy, bromophenoxy, Examples include a phenoxy group, a triloxy group, a cumenyloxy group, and a methoxyphenoxy group.
- arylalkyloxy groups include benzyloxy, bromobenzyloxy, benzobenzyloxy, nitrobenzyloxy, dinitrobenzyloxy, methoxybenzyloxy, phenethyloxy, phenylpropyloxy, and phenyl. And a dipentyloxy group.
- the alkyl group represented by (:, represents a linear or branched alkyl group having 1 to 10 carbon atoms, such as a methyl group, an ethyl group, a propyl group, an isopropyl group, and a butyl group.
- Alkenyl group means a group having 1 or 2 or more double bonds at any position of a linear or branched alkyl group having 2 to 10 carbon atoms, for example, a vinyl group, Examples thereof include an aryl group, a 1-propenyl group, an isopropyl group, a 3-butenyl group, a 1,3-butenyl group, and a 7-octenyl group.
- Alkynyl group means a group having one or more triple bonds at any position of a linear or branched alkyl group having 2 to 10 carbon atoms, such as ethynyl group, 2 _Propynyl group, 2-pentynyl group, 4-octynyl group and the like.
- cycloalkyl group examples include: unsubstituted cycloalkyl groups such as cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclohexyl group, cycloheptyl group, cyclononyl group, and 4-fluorocyclohexyl group, Halogen atoms such as 4,4-difluorocyclohexyl group, 4-methoxycyclohexyl group, 2-methylcyclohexyl group, and 4-trifluoromethylcyclohexyl group; C 1 ; An alkyl group of. And a cycloalkyl group having one or more substituents such as an alkyloxy group.
- C 3 _ As examples of C i _ 5 alkyl group substituted with a cycloalkyl group, cyclo propyl methyl, cyclobutyl E methyl group, cyclopentylmethyl group, consequent Examples thereof include a hexylmethyl group, a cycloheptylmethyl group, a cyclononylbutyl group, and a 4-fluoromethylhexylmethyl group.
- Pharmaceutically acceptable salts include, for example, salts with alkali metals such as sodium and potassium, salts with alkaline earth metals such as calcium and magnesium, ammonium, methylamine, dimethylamine, cyclopentylamine, benzyla Examples thereof include salts with min, piperidine, monoethanolamine, jetanolamine, monomethylmonoethanolamine, tromethamine, lysine, tris (hydroxymethyl) aminomethane, and the like.
- Z is the formula (CH 2 ) K A (CH 2 ) R A '(CH 2 )!
- Z is the formula (CH 2 ) k B (CH 2 ) h B, (CH 2 ) q
- Z is the formula (CH 2 ) K _, B '(CH 2 ) Q —
- One part of the prostaglandin derivative serving as the active ingredient of the present invention is a known compound disclosed in the following gazettes.
- X is o; or;. Shows the 3-substituted halogen atom
- Y represents an ethylene group, a vinylene group or Echiniren group
- R 1 is ⁇ 3 cycloalkyl group
- R 2 represents a group represented by C_ ⁇ 2 R 3
- R 3 Represents a hydrogen atom, (: represents a linear or branched alkyl group of 4 or a linear or branched alkenyl group of C 2 _ 4
- n represents an integer of 1 to 4
- p represents 0, 1 or 2.
- the prostaglandin derivative represented by the formula (1) can be produced by the production methods of Reaction Formulas 1 and 2.
- TBS represents a tert- heptyl dimethylsilyl group
- R 31 is _ 4 alkyl or C 2 - shows a 4 alkenyl group
- pi is 1 or 2
- Z ′ represents a halogen atom
- X, Y, R 1 and n are as defined above.
- a compound of the formula (II ⁇ ⁇ ) is used.
- Y is an ethynylene group.
- the compound of the formula (III) is reacted at 0 to 30 ° C. to obtain the compound of the formula (III).
- bases eg, organic amines such as triethylamine, diisopropylamine, pyridine, and dimethylaniline
- polyvinylpyrrolidone diisopropylaminomethyl-polystyrene
- (Piperidinomethyl) Base resin such as polystyrene) 0.05 to 2 equivalents in an organic solvent (for example, benzene, toluene, xylene, n-hexane, n-pentane, acetone, etc.) in one 78-100 ° C
- the compound of formula (VI) can also be obtained by reacting (3) Potassium borohydride, sodium borohydride, sodium cyanoborohydride, lithium tri-sec-butylpollohydride, diisobutylaluminum hydride "BHT (2,6-di-tert-butyl-p —Cresol) in a solvent such as 0.5 to 5 equivalents in an organic solvent (eg, tetrahydrofuran, getyl ether, ethyl alcohol, methyl alcohol, toluene) at —78 to 40 ° C. VII) and a compound of the formula (VI I ′)
- bromination and fluorination can also be performed by a usual method.
- bromination can be obtained by reacting 1 to 10 equivalents of carbon tetrabromide in acetonitrile in the presence of 1 to 10 equivalents of triphenylphosphine and 1 to 10 equivalents of pyridine.
- the fluorination can be obtained, for example, by reacting 5 to 20 equivalents of getylaminosulfur trifluoride (DAST) in methylene chloride.
- DAST getylaminosulfur trifluoride
- a compound of formula (VIII) (or formula (VIII ')) in a suitable inert organic solvent (eg, tetrahydrofuran, getyl ether, etc.) in a base (eg, alkyllithium such as n-butyllithium).
- a suitable inert organic solvent eg, tetrahydrofuran, getyl ether, etc.
- a base eg, alkyllithium such as n-butyllithium.
- the compound of the formula (Ia) (or the compound of the formula (Ia ')) is added to a buffer such as a phosphate buffer or a tris-hydrochloride buffer, and if necessary, an organic solvent (e.g., acetone, methanol, ethanol, etc.).
- a buffer such as a phosphate buffer or a tris-hydrochloride buffer
- an organic solvent e.g., acetone, methanol, ethanol, etc.
- formula (lb) (or formula (lb ')) can be obtained by hydrolysis by reacting with an enzyme using water-miscible enzyme.
- Enzymes produced by microorganisms for example, enzymes produced by microorganisms belonging to the genera Candida and Pseudomonas
- enzymes produced from animal organs for example, enzymes prepared from bush liver and pig tent
- Specific examples of commercially available enzymes include lipase VII (manufactured by Sigma and derived from Candida microorganism), lipase AY (manufactured by Amano Pharmaceutical, and derived from Candida microorganism), and lipase PS (manufactured by Candida).
- Lipase MF (manufactured by Amano Pharmaceuticals, derived from Pseudomonas spp.), PLE (manufactured by Sigma Co., Ltd., prepared from bushu liver)
- Protein lipase (manufactured by Tokyo Chemical Industry Co., Ltd., prepared from Buta Teng Lean)
- the amount of the enzyme to be used may be appropriately selected according to the titer of the enzyme and the amount of the substrate [compound of the formula (Ia) (or the compound of the formula Ia ')]. Double weight parts.
- the reaction temperature is 25-50 ° C, preferably 30-40 ° C.
- the PG derivative according to the present invention by hydrolyzing the compound of the formula (Ia) (or the formula (la ′)) in a solvent usually used for hydrolysis using a base, the PG derivative according to the present invention, the formula (lb) (Or the formula (lb ')).
- the base used here include lithium hydroxide and potassium carbonate
- the solvent include acetonitrile, acetone, methanol, ethanol, water, and a mixed solvent thereof.
- Typical compounds of the formula [1] according to the present invention include the following compounds.
- cyc5m cyclopenty remethinole group
- E-CH CH: trans vinylene group cyc6: cyclohexyl group
- the antipruritic agent of the present invention is not particularly limited as long as it reduces or eliminates pruritus, and is particularly effective for itching due to atopy. From this point, the antipruritic agent of the present invention includes a drug for preventing or treating atopic symptoms.
- the “pruritic condition” refers to a condition having localized or generalized itching and associated inflammation on the skin and mucous membranes.
- scabies juniper measles, eczema, xerosis (senile xeroderma, skin deficiency eczema, etc.), psoriasis, pruritus cutis, and prurigo.
- atopic symptom refers to a symptom having localized or generalized itching due to atopy and inflammation related thereto on the skin and mucous membranes, ie, pruritic symptom due to atopy (including pruritus nervosa) Say. Examples include atopic dermatitis and atopic conjunctivitis.
- atopic dermatitis refers to a disease in which pruritus eczema is the main lesion, which is repeatedly exacerbated and ameliorated, and is likely to occur in individuals who are predisposed to atopy.
- the antipruritic agent of the present invention can be administered orally, parenterally or topically. .
- the dosage of the active ingredient in the antipruritic agent of the present invention can be appropriately increased or decreased depending on the patient's body weight, age, sex, etc., but is usually 1 ng to 10 mg, preferably 0.1 to 10 mg per administration. Yes Can be administered once to several times a day.
- the antipruritic agent of the present invention can be prepared as a pharmaceutical composition using carriers, excipients, and other additives commonly used in the preparation of active ingredients.
- Pharmaceutical carriers and excipients include, for example, water, ethanol, lactose, microcrystalline cellulose, liquid paraffin, hydrogenated oil, honey, squalane, stearyl alcohol, ethylene glycol, and other commonly used substances. be able to.
- additives examples include disintegrants (starch, etc.), binders ⁇ hydroxypropylcellulose, low-substituted hydroxypropylcellulose ⁇ , lubricants (talc, glyceryl stearate, etc.), antioxidants, preservatives (paraben, etc.). Etc.), coating agents (gelatin, hydroxypropylcellulose, etc.), coloring agents, flavoring agents, whitening agents (sodium ellagate, etc.), surfactants (sorbitan fatty acid esters, etc.) 003/010051), plasticizers, moisturizers (glycerin, propylene glycol, polyethylene daricol, hyaluronic acid, etc.).
- the antipruritic agent of the present invention is in the form of tablets, granules, powders, capsules, solutions, gels, plasters, ointments, creams, patches, aerosols, etc. It can be administered in the form of agents (nasal drops, eye drops) and the like.
- Preferred dosage forms include external preparations because they can be directly administered to the affected area, are easy to administer, and reduce the possibility of systemic side effects.
- the “external preparation” includes a liquid preparation for external use, an aerosol, a powder for external use, an ointment, a cream, a gel, a plaster, a patch and the like.
- the present invention will be described in more detail with reference to the following Examples and Test Examples, but the present invention is not limited thereto. Various changes and modifications can be made by those skilled in the art based on the description of the present invention, and these changes and modifications are also included in the present invention.
- drug concentration means w / v (weight / volume%).
- the following components were mixed and uniformly emulsified, and a fragrance was further added to obtain 500 g of a cream.
- Test example 1 Effect on spontaneous pruritus behavior of NC mice
- Magnets were implanted in both feet of a 20-week-old NC / Nga mouse (purchased by SLC) with a body weight of about 30 g and developed atopic dermatitis, and the movement of the feet was sensed using the magnetic force to detect the pruritus measurement system (Neuroscience). Company: When the mouse moves, the magnet also moves, causing a current in the coil, and the movement of the magnet causes a change in the current, which is detected, measured, and analyzed. Of the pulling actions, those with a duration of 1.5 seconds or more were regarded as pruritic actions, and the number of times was continuously measured.
- the pruritic behavior has a daily rhythm
- the daily pruritus rhythm of each animal was measured for 24 hours from the day before the test, and each drug dissolved in 100% ethanol was added to the back at a rate of 0.2 ml / mouse. It was applied to the skin. Then, the pruritic behavior for 24 hours was measured, and the number of pruritic behavior before and after drug administration was compared.
- the experimental data calculated the pruritus suppression rate from the total number of pruritus 24 hours before and after drug application.
- the significance test was performed using a corresponding t-test (pai red t-test) for the number of pruritus before and after drug application in each animal of each drug concentration application group.
- Itching suppression rate (%) (itch number before application-number of itch after application) xl 00 Number of itching before application (experimental results)
- mice After living together for 2 weeks, the purchased mice were taken out and reared in separate cages at 8 mice per cage for about 14 weeks. Immediately before the start of drug application, mice were sorted so that the dermatitis score in each cage became equal, and four mice were bred per cage.
- Tacrolimus (Fujisawa Pharmaceutical) used what was purchased.
- Dermatitis score Once / week, skin irritations were observed and measured.
- Magnets were implanted in both feet of a 20-week-old atopic dermatitis-causing NC / Nga mouse (purchased by SLC) weighing about 30 and the movement of the feet was sensed by sensing the magnetic force. ). Of the dragging actions, those that were 1.5 seconds or longer were regarded as pruritic actions, and the number of times of the action was continuously measured. Since the pruritic behavior has intraday rhythm, the intraday pruritus rhythm of each animal was measured 24 hours from the day before the test, and Compound 3 (0.1%) and Compound 11 (0. 1%) or compound 12
- dermatitis such as atopic dermatitis, atopic conjunctivitis, scabies, measles and xeroderma can be prevented or improved. It became possible to provide drugs.
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Detergent Compositions (AREA)
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE60322395T DE60322395D1 (de) | 2002-08-09 | 2003-08-07 | Antipruritisches mittel |
JP2004527356A JP3678366B2 (ja) | 2002-08-09 | 2003-08-07 | 止痒剤 |
CA2465103A CA2465103C (en) | 2002-08-09 | 2003-08-07 | Use of a prostaglandin derivative as an anti-pruritic agent |
AU2003254850A AU2003254850B2 (en) | 2002-08-09 | 2003-08-07 | Antipruritic agent |
MXPA04004371A MXPA04004371A (es) | 2002-08-09 | 2003-08-07 | Agente antipruritico. |
DK03784565T DK1527781T3 (da) | 2002-08-09 | 2003-08-07 | Antipruritisk middel |
EP03784565A EP1527781B1 (en) | 2002-08-09 | 2003-08-07 | Antipruritic agent |
US10/493,693 US7718701B2 (en) | 2002-08-09 | 2003-08-07 | Antipruritic agent |
NO20042053A NO20042053L (no) | 2002-08-09 | 2004-05-18 | Kloestillende middel |
US11/049,641 US7737182B2 (en) | 2002-08-09 | 2005-02-04 | Pharmaceuticals for xerosis |
HK05108508.3A HK1076391A1 (en) | 2002-08-09 | 2005-09-27 | Antipruritic agent |
US12/762,876 US20100204320A1 (en) | 2002-08-09 | 2010-04-19 | Pharmaceuticals for xerosis |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002-234011 | 2002-08-09 | ||
JP2002234011 | 2002-08-09 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10493693 A-371-Of-International | 2001-08-07 | ||
US11/049,641 Continuation-In-Part US7737182B2 (en) | 2002-08-09 | 2005-02-04 | Pharmaceuticals for xerosis |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004014394A1 true WO2004014394A1 (ja) | 2004-02-19 |
Family
ID=31711882
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/010051 WO2004014394A1 (ja) | 2002-08-09 | 2003-08-07 | 止痒剤 |
Country Status (18)
Country | Link |
---|---|
US (1) | US7718701B2 (ja) |
EP (1) | EP1527781B1 (ja) |
JP (1) | JP3678366B2 (ja) |
KR (1) | KR100904583B1 (ja) |
CN (1) | CN100408039C (ja) |
AT (1) | ATE401895T1 (ja) |
AU (1) | AU2003254850B2 (ja) |
CA (1) | CA2465103C (ja) |
DE (1) | DE60322395D1 (ja) |
DK (1) | DK1527781T3 (ja) |
ES (1) | ES2309380T3 (ja) |
HK (1) | HK1076391A1 (ja) |
MX (1) | MXPA04004371A (ja) |
NO (1) | NO20042053L (ja) |
PL (1) | PL373819A1 (ja) |
PT (1) | PT1527781E (ja) |
TW (1) | TW200404053A (ja) |
WO (1) | WO2004014394A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006085655A1 (ja) * | 2005-02-14 | 2006-08-17 | Taisho Pharmaceutical Co., Ltd. | 軟膏剤 |
WO2008018592A1 (fr) | 2006-08-11 | 2008-02-14 | Taisho Pharmaceutical Co., Ltd. | Préparation externe comprenant un dérivé de la prostaglandine |
WO2009004873A1 (ja) | 2007-06-29 | 2009-01-08 | Taisho Pharmaceutical Co., Ltd. | プロスタグランジン誘導体含有水性液剤 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040266880A1 (en) * | 2002-02-22 | 2004-12-30 | Fumie Sato | Antipruritics |
CN1283624C (zh) | 2002-07-12 | 2006-11-08 | 大正制药株式会社 | 前列腺素衍生物 |
WO2004014394A1 (ja) | 2002-08-09 | 2004-02-19 | Taisho Pharmaceutical Co.,Ltd. | 止痒剤 |
US7737182B2 (en) * | 2002-08-09 | 2010-06-15 | Taisho Pharmaceutical Co., Ltd. | Pharmaceuticals for xerosis |
CA2624141C (en) | 2005-10-03 | 2014-07-08 | Nippon Shinyaku Co., Ltd. | Quinazoline derivative and pharmaceutical |
Citations (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0069696A2 (de) * | 1981-07-03 | 1983-01-12 | Schering Aktiengesellschaft | 9-Fluor-prostaglandinderivate, Verfahren zur Herstellung und Verwendung als Arzneimittel |
WO1985000367A1 (en) * | 1983-07-08 | 1985-01-31 | Schering Aktiengesellschaft | 11-halogene-prostane derivatives, process for obtaining them and utilization thereof as drugs |
WO1985002841A1 (en) * | 1983-12-22 | 1985-07-04 | Schering Aktiengesellschaft | 9-halogen-delta2-prostaglandine derivatives, preparation process and utilization thereof as drugs |
WO1989000559A1 (en) * | 1987-07-17 | 1989-01-26 | Schering Aktiengesellschaft Berlin Und Bergkamen | 9-halogen-(z)-prostaglandin derivatives, process for manufacturing them, and their use as drugs |
EP0652211A1 (en) * | 1992-07-24 | 1995-05-10 | Taisho Pharmaceutical Co. Ltd | Prostaglandin derivative |
EP0666256A1 (en) * | 1992-10-20 | 1995-08-09 | Taisho Pharmaceutical Co. Ltd | Prostaglandine derivative |
JPH07242622A (ja) * | 1994-03-07 | 1995-09-19 | Taisho Pharmaceut Co Ltd | プロスタグランジン誘導体およびその使用 |
JPH07285929A (ja) * | 1994-04-19 | 1995-10-31 | Taisho Pharmaceut Co Ltd | プロスタグランジン誘導体 |
WO1996016935A1 (fr) * | 1994-11-30 | 1996-06-06 | Taisho Pharmaceutical Co., Ltd. | Derive de prostaglandines |
EP0737676A1 (en) * | 1993-12-29 | 1996-10-16 | Taisho Pharmaceutical Co. Ltd | Prostaglandin derivative, salt thereof, and use thereof |
JPH09286775A (ja) * | 1996-04-24 | 1997-11-04 | Taisho Pharmaceut Co Ltd | プロスタグランジン誘導体 |
WO1998027971A1 (en) * | 1996-12-23 | 1998-07-02 | Michael Albert Kamm | Pharmaceutical composition for treating fecal incontinence and anal itch |
EP0860430A2 (en) * | 1997-02-04 | 1998-08-26 | Ono Pharmaceutical Co., Ltd. | Omega-cycloalkyl-prostaglandin E2 derivatives |
US5807892A (en) * | 1994-09-30 | 1998-09-15 | Alcon Laboratories, Inc. | Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension |
WO1999025358A1 (en) * | 1997-11-19 | 1999-05-27 | Allergan Sales, Inc. | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
JP2000273083A (ja) * | 1999-03-19 | 2000-10-03 | Taisho Pharmaceut Co Ltd | プロスタグランジン誘導体 |
EP1083168A1 (en) * | 1998-05-25 | 2001-03-14 | Taisho Pharmaceutical Co., Ltd | Prostaglandin derivative |
JP2001089443A (ja) * | 1999-07-19 | 2001-04-03 | Taisho Pharmaceut Co Ltd | プロスタグランジン誘導体 |
JP2001122786A (ja) * | 1999-10-20 | 2001-05-08 | Taisho Pharmaceut Co Ltd | 睡眠誘発剤 |
EP1097922A1 (en) * | 1998-07-15 | 2001-05-09 | Ono Pharmaceutical Co., Ltd. | 5-thia-omega-substituted phenyl-prostaglandin e derivatives, process for producing the same and drugs containing the same as the active ingredient |
JP2001151749A (ja) * | 1999-11-24 | 2001-06-05 | Taisho Pharmaceut Co Ltd | プロスタグランジン誘導体 |
WO2001049661A1 (fr) * | 2000-01-05 | 2001-07-12 | Ono Pharmaceutical Co., Ltd. | ALCOOLS 5-THIA-φ-(PHENYLE SUBSTITUES)- PROSTAGLANDINE E, PROCESSUS DE PREPARATION DE CES ALCOOLS ET PREPARATIONS PHARMACEUTIQUES CONTENANT CES ALCOOLS COMME PRINCIPE ACTIF. |
WO2002016311A1 (fr) * | 2000-08-22 | 2002-02-28 | Ono Pharmaceutical Co., Ltd. | Derives d'acide carboxylique, procede de production de ceux-ci et medicaments contenant ceux-ci comme principe actif |
WO2002020462A1 (fr) * | 2000-09-01 | 2002-03-14 | Ono Pharmaceutical Co., Ltd. | Derives d'acide benzoique et medicaments possedant ces derniers comme principe actif |
EP1211242A1 (en) * | 1999-09-10 | 2002-06-05 | Taisho Pharmaceutical Co., Ltd | Prostaglandin derivatives |
WO2003070252A1 (fr) * | 2002-02-22 | 2003-08-28 | Taisho Pharmaceutical Co., Ltd. | Agents antiprurigineux |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4983629A (en) | 1983-07-08 | 1991-01-08 | Schering Aktiengesellschaft | 11-haloprostane derivatives, processes for their preparation and their use as medicinal agents |
US5891910A (en) | 1987-07-17 | 1999-04-06 | Schering Aktiengesellschaft | 9-halogen-(Z) prostaglandin derivatives, process for their production and their use as pharmaceutical agents |
US5591446A (en) | 1989-04-04 | 1997-01-07 | Beiersdorf, A.G. | Methods and agents for the prophylaxis of atopy |
US5252602A (en) | 1991-10-11 | 1993-10-12 | Rafeul Alam | Effects of misoprostol on allergic responses |
EP0583482B1 (en) | 1992-02-07 | 1999-12-29 | Kaken Pharmaceutical Co., Ltd. | Remedy for wound or hemorrhoid |
JPH0971539A (ja) | 1995-09-08 | 1997-03-18 | Mochida Pharmaceut Co Ltd | 外用鎮痒剤 |
JPH09169638A (ja) | 1995-10-18 | 1997-06-30 | Sekisui Chem Co Ltd | 皮膚疾患治療用外用剤 |
US5599838A (en) * | 1996-02-23 | 1997-02-04 | Taisho Pharmaceutical Co., Ltd. | Prostaglandin derivatives |
WO1997045114A1 (en) | 1996-05-30 | 1997-12-04 | Lysis Corporation | The treatment of vascular disease with prostaglandins via a sustained-release dermal patch |
JPH10316564A (ja) | 1997-05-21 | 1998-12-02 | Sekisui Chem Co Ltd | 鎮痒鎮痛外用剤 |
JPH1180031A (ja) | 1997-07-14 | 1999-03-23 | Sekisui Chem Co Ltd | 外用剤及び経皮又は経粘膜吸収性を増進する方法 |
JPH11199478A (ja) | 1998-01-05 | 1999-07-27 | Hiroshi Nagoshi | レチノイド並びにプロスタグランジンd▲2▼誘導体の抗炎症薬としての使用 |
DE69925270T2 (de) | 1998-06-03 | 2006-02-23 | Shionogi & Co., Ltd. | Mittel zur linderung von juckreiz, enthaltend pgd2- antagonisten |
US6506789B2 (en) | 1998-06-03 | 2003-01-14 | Shionogi & Co., Ltd. | Methods for the treatment of itching comprising administering PGD2 receptor antagonist |
DE69932180T2 (de) | 1998-11-23 | 2007-06-14 | Proteome Sciences, Inc., Houston | Verfahren und zusammensetzungen zur schmerzbehandlung |
US6191154B1 (en) | 1998-11-27 | 2001-02-20 | Case Western Reserve University | Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases |
DE60008399T2 (de) | 1999-09-14 | 2004-12-09 | Merck Frosst Canada & Co, Kirkland | Carbonsäuren und acylsulfonamide, solche verbindungen enthaltende zubereitungen und behandlungsmethoden |
EP1308162A1 (en) * | 1999-11-24 | 2003-05-07 | Taisho Pharmaceutical Co., Ltd | Pernasal preparation |
JP2001220355A (ja) | 2000-02-07 | 2001-08-14 | Teijin Ltd | PPARβ/δ及びγリガンドからなる肥満細胞活性化抑制剤 |
US6878522B2 (en) | 2000-07-07 | 2005-04-12 | Baiyong Li | Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2 |
WO2002045718A1 (en) | 2000-12-08 | 2002-06-13 | Institut Pasteur De Lille | Use of active compounds capable of modulating the intracellular pathway triggered by the dp receptor in langerhans cells |
US20040266880A1 (en) | 2002-02-22 | 2004-12-30 | Fumie Sato | Antipruritics |
WO2004014394A1 (ja) | 2002-08-09 | 2004-02-19 | Taisho Pharmaceutical Co.,Ltd. | 止痒剤 |
US7737182B2 (en) | 2002-08-09 | 2010-06-15 | Taisho Pharmaceutical Co., Ltd. | Pharmaceuticals for xerosis |
-
2003
- 2003-08-07 WO PCT/JP2003/010051 patent/WO2004014394A1/ja active IP Right Grant
- 2003-08-07 DE DE60322395T patent/DE60322395D1/de not_active Expired - Lifetime
- 2003-08-07 PL PL03373819A patent/PL373819A1/xx not_active Application Discontinuation
- 2003-08-07 KR KR1020047008144A patent/KR100904583B1/ko not_active IP Right Cessation
- 2003-08-07 ES ES03784565T patent/ES2309380T3/es not_active Expired - Lifetime
- 2003-08-07 EP EP03784565A patent/EP1527781B1/en not_active Expired - Lifetime
- 2003-08-07 AU AU2003254850A patent/AU2003254850B2/en not_active Ceased
- 2003-08-07 PT PT03784565T patent/PT1527781E/pt unknown
- 2003-08-07 US US10/493,693 patent/US7718701B2/en not_active Expired - Fee Related
- 2003-08-07 JP JP2004527356A patent/JP3678366B2/ja not_active Expired - Fee Related
- 2003-08-07 DK DK03784565T patent/DK1527781T3/da active
- 2003-08-07 CN CNB038017350A patent/CN100408039C/zh not_active Expired - Fee Related
- 2003-08-07 CA CA2465103A patent/CA2465103C/en not_active Expired - Fee Related
- 2003-08-07 AT AT03784565T patent/ATE401895T1/de active
- 2003-08-07 MX MXPA04004371A patent/MXPA04004371A/es active IP Right Grant
- 2003-08-08 TW TW092121887A patent/TW200404053A/zh not_active IP Right Cessation
-
2004
- 2004-05-18 NO NO20042053A patent/NO20042053L/no not_active Application Discontinuation
-
2005
- 2005-09-27 HK HK05108508.3A patent/HK1076391A1/xx not_active IP Right Cessation
Patent Citations (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0069696A2 (de) * | 1981-07-03 | 1983-01-12 | Schering Aktiengesellschaft | 9-Fluor-prostaglandinderivate, Verfahren zur Herstellung und Verwendung als Arzneimittel |
WO1985000367A1 (en) * | 1983-07-08 | 1985-01-31 | Schering Aktiengesellschaft | 11-halogene-prostane derivatives, process for obtaining them and utilization thereof as drugs |
WO1985002841A1 (en) * | 1983-12-22 | 1985-07-04 | Schering Aktiengesellschaft | 9-halogen-delta2-prostaglandine derivatives, preparation process and utilization thereof as drugs |
WO1989000559A1 (en) * | 1987-07-17 | 1989-01-26 | Schering Aktiengesellschaft Berlin Und Bergkamen | 9-halogen-(z)-prostaglandin derivatives, process for manufacturing them, and their use as drugs |
EP0652211A1 (en) * | 1992-07-24 | 1995-05-10 | Taisho Pharmaceutical Co. Ltd | Prostaglandin derivative |
EP0666256A1 (en) * | 1992-10-20 | 1995-08-09 | Taisho Pharmaceutical Co. Ltd | Prostaglandine derivative |
EP0737676A1 (en) * | 1993-12-29 | 1996-10-16 | Taisho Pharmaceutical Co. Ltd | Prostaglandin derivative, salt thereof, and use thereof |
JPH07242622A (ja) * | 1994-03-07 | 1995-09-19 | Taisho Pharmaceut Co Ltd | プロスタグランジン誘導体およびその使用 |
JPH07285929A (ja) * | 1994-04-19 | 1995-10-31 | Taisho Pharmaceut Co Ltd | プロスタグランジン誘導体 |
US5807892A (en) * | 1994-09-30 | 1998-09-15 | Alcon Laboratories, Inc. | Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension |
WO1996016935A1 (fr) * | 1994-11-30 | 1996-06-06 | Taisho Pharmaceutical Co., Ltd. | Derive de prostaglandines |
JPH09286775A (ja) * | 1996-04-24 | 1997-11-04 | Taisho Pharmaceut Co Ltd | プロスタグランジン誘導体 |
WO1998027971A1 (en) * | 1996-12-23 | 1998-07-02 | Michael Albert Kamm | Pharmaceutical composition for treating fecal incontinence and anal itch |
EP0860430A2 (en) * | 1997-02-04 | 1998-08-26 | Ono Pharmaceutical Co., Ltd. | Omega-cycloalkyl-prostaglandin E2 derivatives |
WO1999025358A1 (en) * | 1997-11-19 | 1999-05-27 | Allergan Sales, Inc. | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
EP1082961A1 (en) * | 1998-05-25 | 2001-03-14 | Taisho Pharmaceutical Co., Ltd | Sleep inducing agent |
EP1083168A1 (en) * | 1998-05-25 | 2001-03-14 | Taisho Pharmaceutical Co., Ltd | Prostaglandin derivative |
EP1097922A1 (en) * | 1998-07-15 | 2001-05-09 | Ono Pharmaceutical Co., Ltd. | 5-thia-omega-substituted phenyl-prostaglandin e derivatives, process for producing the same and drugs containing the same as the active ingredient |
JP2000273083A (ja) * | 1999-03-19 | 2000-10-03 | Taisho Pharmaceut Co Ltd | プロスタグランジン誘導体 |
JP2001089443A (ja) * | 1999-07-19 | 2001-04-03 | Taisho Pharmaceut Co Ltd | プロスタグランジン誘導体 |
EP1211242A1 (en) * | 1999-09-10 | 2002-06-05 | Taisho Pharmaceutical Co., Ltd | Prostaglandin derivatives |
JP2001122786A (ja) * | 1999-10-20 | 2001-05-08 | Taisho Pharmaceut Co Ltd | 睡眠誘発剤 |
JP2001151749A (ja) * | 1999-11-24 | 2001-06-05 | Taisho Pharmaceut Co Ltd | プロスタグランジン誘導体 |
WO2001049661A1 (fr) * | 2000-01-05 | 2001-07-12 | Ono Pharmaceutical Co., Ltd. | ALCOOLS 5-THIA-φ-(PHENYLE SUBSTITUES)- PROSTAGLANDINE E, PROCESSUS DE PREPARATION DE CES ALCOOLS ET PREPARATIONS PHARMACEUTIQUES CONTENANT CES ALCOOLS COMME PRINCIPE ACTIF. |
WO2002016311A1 (fr) * | 2000-08-22 | 2002-02-28 | Ono Pharmaceutical Co., Ltd. | Derives d'acide carboxylique, procede de production de ceux-ci et medicaments contenant ceux-ci comme principe actif |
WO2002020462A1 (fr) * | 2000-09-01 | 2002-03-14 | Ono Pharmaceutical Co., Ltd. | Derives d'acide benzoique et medicaments possedant ces derniers comme principe actif |
WO2003070252A1 (fr) * | 2002-02-22 | 2003-08-28 | Taisho Pharmaceutical Co., Ltd. | Agents antiprurigineux |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006085655A1 (ja) * | 2005-02-14 | 2006-08-17 | Taisho Pharmaceutical Co., Ltd. | 軟膏剤 |
JPWO2006085655A1 (ja) * | 2005-02-14 | 2008-06-26 | 大正製薬株式会社 | 軟膏剤 |
US7888392B2 (en) | 2005-02-14 | 2011-02-15 | Taisho Pharmaceutical Co., Ltd. | Ointment |
WO2008018592A1 (fr) | 2006-08-11 | 2008-02-14 | Taisho Pharmaceutical Co., Ltd. | Préparation externe comprenant un dérivé de la prostaglandine |
WO2009004873A1 (ja) | 2007-06-29 | 2009-01-08 | Taisho Pharmaceutical Co., Ltd. | プロスタグランジン誘導体含有水性液剤 |
US8044104B2 (en) | 2007-06-29 | 2011-10-25 | Taisho Pharmaceutical Co., Ltd | Prostaglandin derivative-containing aqueous liquid preparation |
Also Published As
Publication number | Publication date |
---|---|
DK1527781T3 (da) | 2008-11-17 |
AU2003254850A1 (en) | 2004-02-25 |
NO20042053L (no) | 2004-05-18 |
EP1527781B1 (en) | 2008-07-23 |
ATE401895T1 (de) | 2008-08-15 |
HK1076391A1 (en) | 2006-01-20 |
PL373819A1 (en) | 2005-09-19 |
CN100408039C (zh) | 2008-08-06 |
DE60322395D1 (de) | 2008-09-04 |
CA2465103A1 (en) | 2004-02-19 |
TWI328574B (ja) | 2010-08-11 |
KR20050026375A (ko) | 2005-03-15 |
AU2003254850B2 (en) | 2008-05-15 |
CA2465103C (en) | 2011-04-26 |
US7718701B2 (en) | 2010-05-18 |
TW200404053A (en) | 2004-03-16 |
EP1527781A1 (en) | 2005-05-04 |
JP3678366B2 (ja) | 2005-08-03 |
CN1620297A (zh) | 2005-05-25 |
JPWO2004014394A1 (ja) | 2005-12-02 |
MXPA04004371A (es) | 2004-08-13 |
ES2309380T3 (es) | 2008-12-16 |
EP1527781A4 (en) | 2006-12-13 |
US20050009917A1 (en) | 2005-01-13 |
PT1527781E (pt) | 2008-08-12 |
KR100904583B1 (ko) | 2009-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7737182B2 (en) | Pharmaceuticals for xerosis | |
US20020010128A1 (en) | Treatment of hyperproliferative, inflammatory and related mucocutaneous disorders using inhibitors of mevalonate synthesis and metabolism | |
WO2004014394A1 (ja) | 止痒剤 | |
Korting et al. | The hydroxypyridones: a class of antimycotics of its own | |
JP2010184903A (ja) | 外用医薬組成物 | |
JP2005139194A (ja) | 止痒剤 | |
JP2002047188A (ja) | β−グルコセレブロシダーゼ遺伝子の発現の低下抑制剤 | |
Fretland et al. | Dermal inflammation in primates, mice, and guinea pigs: Attenuation by second-generation leukotriene B 4 receptor antagonist, SC-53228 | |
WO2013013178A1 (en) | Sesquiterpenes for antifungal applications | |
Ezeamuzie et al. | Anti-allergic, anti-asthmatic and anti-inflammatory effects of an oxazolidinone hydroxamic acid derivative (PH-251)–A novel dual inhibitor of 5-lipoxygenase and mast cell degranulation | |
JPH09510199A (ja) | キノリン−3−カルボキシアミド化合物の新規な使用 | |
NZ205587A (en) | Composition comprising undecylenic acid for treating herpes simplex i | |
WO1998051313A1 (fr) | Remedes contre les yeux secs | |
JPH08283150A (ja) | 抗炎症剤 | |
JP4477504B2 (ja) | 鎮痒剤 | |
JPH08231389A (ja) | 抗皮膚炎剤 | |
JP2001163783A (ja) | 皮膚疾患治療用外用剤 | |
JP2007091643A (ja) | 医療用抗白癬菌剤 | |
Linn | The Use of Dapsone in Dermatology. | |
US9408844B2 (en) | Methods for treating inflammatory conditions | |
JP2004501963A (ja) | アルコール中毒症及びアルコール依存症の治療の為の方法及び組成物 | |
JPH1149675A (ja) | Ab5366物質を含むアレルギー性疾患の予防、治療薬と酵素阻害剤 | |
Rosenthale et al. | Prostaglandin F2s | |
FR2469180A1 (fr) | Medicament a base de derives de l'acide apovincaminique pour le traitement des maladies de la peau associees a une proliferation pathologique des cellules telles que le psoriasis | |
Kan | Investigation into the mechanisms of prostanoid-induced emesis in the ferret and Suncus murinus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 2004527356 Country of ref document: JP |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2465103 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10493693 Country of ref document: US Ref document number: 2003784565 Country of ref document: EP Ref document number: 373819 Country of ref document: PL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003254850 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2004/004371 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020047008144 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038017350 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2003784565 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2003784565 Country of ref document: EP |